Stocks of out-of-home entertainment companies got a boost from biotech company Moderna’s announcement on Tuesday. As markets reacted enthusiastically to a promising coronavirus vaccine trial, shares of concert promoter Live Nation leaped 12.2% to $52.09 on Wednesday (July 15) before closing at $51.84, up 11.7%.
On Tuesday, biotech company Moderna published the results of an initial study for a coronavirus vaccine called mRNA-1273. The vaccine “elicits a robust immune response” in all trial participants, said chief medical officer Tal Zaks in a statement, and will enter the next phase -- with approximately 30,000 participants -- later this month.
Read more on billboard.com